| Literature DB >> 30111967 |
S F McGee1, W AlGhareeb1, C H Ahmad2, D Armstrong2, S Babak1, S Berry1, J Biagi1, C Booth1, D Bossé3, P Champion4, B Colwell5, N Finn6, R Goel1, S Gray6, J Green2, M Harb6, A Hyde1, A Jeyakumar5, D Jonker1, S Kanagaratnam2, P Kavan7, A MacMillan2, A Muinuddin1, N Patil5, G Porter5, E Powell2, R Ramjeesingh5, M Raza6, S Rorke2, M Seal2, F Servidio-Italiano1, J Siddiqui2, J Simms2, L Smithson2, S Snow5, E St-Hilaire6, T Stuckless2, A Tate2, M Tehfe7, M Thirlwell7, E Tsvetkova1, M Valdes1, M Vickers1, K Virik1, S Welch1, C Marginean1, T Asmis1.
Abstract
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including ■ identification and management of hereditary gastric and colorectal cancer (crc);■ palliative systemic therapy for metastatic gastric cancer;■ optimum duration of preoperative radiation in rectal cancer-that is, short- compared with long-course radiation;■ management options for peritoneal carcinomatosis in crc;■ implications of tumour location for treatment and prognosis in crc; and■ new molecular markers in crc.Entities:
Keywords: Guidelines; chemotherapy; colorectal cancer; gastric cancer; hereditary cancer syndromes; immunotherapy; molecular markers; peritoneal carcinomatosis; radiation therapy; rectal cancer
Mesh：
Year: 2018 PMID： 30111967 PMCID： PMC6092057 DOI： 10.3747/co.25.4083
Source DB: PubMed Journal: Curr Oncol ISSN： 1198-0052 Impact factor: 3.677